Chimeric Antigen-Receptor-Modified T Cells Targeting B7-H3
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07949448. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Chimeric Antigen-Receptor-Modified T Cells Targeting B7-H3 for the Treatment of High-Grade Gliomas (Sonia's Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
LCCC 2534-ATL is an early-stage (Phase 1), single-center clinical study evaluating the safety of CAR T-cell therapy in children and adults with high-grade gliomas (HGGs), which are aggressive brain cancers. The treatment, called iC9-CAR.B7-H3 T cells, uses modified immune cells designed to recognize and attack cancer cells with a protein called B7-H3. The treatment also includes a safety switch (iC9) designed to help stop the modified cells if serious side effects occur. Earlier studies of B7-H3-targeted CAR T-cell therapy have shown encouraging safety results, with some patients experiencing tumor shrinkage. This study will further evaluate the safety and tolerability of the treatment in children and adults with high-grade gliomas type brain tumors. The study will use a 3+3 dose-escalation design to evaluate increasing doses and identify the safest appropriate dose. The results will help determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), which is the dose selected for further study. Participants who qualify will have blood collected to produce the modified T cells. Three treatment doses will be administered two weeks apart. Additional doses may be given. Participants will be monitored for 15 years after treatment ends or is discontinued to assess potential long-term side effects related to genetic modification of the cells.
Study identification
- NCT ID
- NCT07949448
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2026 (Estimated)
- Primary completion
- Oct 31, 2029 (Estimated)
- Completion
- Dec 31, 2044 (Estimated)
- Last update posted
- Nov 19, 2026
2026 – 2044
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of North Carolina at Chapel Hill, Department of Radiation Oncology | Chapel Hill | North Carolina | 27599 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07949448, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.